Dopamine activation of endogenous cannabinoid signaling in dorsal striatum

Nature Neuroscience

Volumn 2, Issue 4, 1999, Pages 358-363

  Giuffrida, A ^a   Parsons, L H ^b   Kerr, T M ^b   Rodriguez De Fonseca F ^c   Navarro, M ^c   Piomelli, D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; QUINPIROLE; RACLOPRIDE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; FACILITATION; FEEDBACK SYSTEM; GAS CHROMATOGRAPHY; MOTOR NERVE CONDUCTION; NERVE EXCITABILITY; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ARACHIDONIC ACIDS; CALCIUM; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ENDOCANNABINOIDS; ETHANOLAMINES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLYCERIDES; HYPERKINESIS; MALE; MICRODIALYSIS; MOTOR ACTIVITY; PALMITIC ACIDS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; POTASSIUM; PYRAZOLES; QUINPIROLE; RACLOPRIDE; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, DOPAMINE D2; RECEPTORS, DRUG; SALICYLAMIDES; SIGNAL TRANSDUCTION; SINGLE-BLIND METHOD; SODIUM; TETRODOTOXIN;

EID: 0033362973     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/7268     Document Type: Article

References (50)

1. Gerfen, C. R. The neostriatal mosaic: multiple levels of compartmental organization. Annu. Rev. Neurosci. 15, 285-320 (1992).
2. Graybiel, A. M., Aosaki, T., Flaherty, A. W. & Kimura, M. The basal ganglia and adaptive motor control. Science 265, 1826-1831 (1994).
3. Chase, T. N., Engber, T. M. & Mouradian, M. M. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv. Neurol. 69, 497-501 (1996).
4. 2 receptor binding. Science 273, 1225-1227 (1996).
5. Eidelberg, D. et al. The metabolic anatomy of Tourette's syndrome. Neurology 48, 927-934 (1997).
6. Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 87, 1932-1936 (1990).
7. Matsuda, L. A., Lolait, S. J., Brownstein, M., Young, A. & Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).
8. Herkenham, M. et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583 (1991).
9. Sim, L. J., Selley, D. E., Xiao, R. & Childers, S. R. Differences in G-protein activation by μ- and δ-opioid, and cannabinoid receptors in rat striatum. Eur. J. Pharmacol. 307, 97-105 (1996).
10. Szabo, B., Dörner, L., Pfreundtner, C., Nörenberg, W. & Starke, K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85, 395-403 (1998).
11. Sañudo-Peña, M. C., Patrick, S. L., Patrick, R. L. & Walker, J. M. Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Neurosci. Lett. 206, 21-24 (1996).
12. Hemming, M. & Yellowlees, P. M. Effective treatment of Tourette's syndrome with marijuana. J. Psychopharmacol. 7, 389-391 (1993).
13. Müller-Vahl, K. R., Schneider, U., Kolbe, H. & Emrich, H. M. Treatment of Tourette-syndrome with delta-9-tetrahydrocannabinol. Am. J. Psychiatry (in press).
14. Devane, W. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992).
15. Di Marzo, V. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691 (1994).
16. Sugiura, T. et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97 (1995).
17. Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90 (1995).
18. Stella, N., Schweitzer, P. & Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778 (1997).
19. Cadas, H., di Tomaso, E. & Piomelli, D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidyl-ethanolamine, in rat brain. J. Neurosci. 17, 1226-1242 (1997).
20. Sugiura, T. et al. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Eur. J. Biochem. 240, 53-62 (1996).
21. 2+-dependent transacylase and phosphodiesterase activities. Biochem. Biophys. Res. Commun. 218, 113-117 (1996).
22. Giuffrida, A. & Piomelli, D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett. 422, 373-376 (1998).
23. Facci, L. et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA 92, 3376-3380 (1995).
24. Calignano, A., La Rana, G., Giuffrida, A. & Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 394, 277-281 (1998).
25. Schmid, H. H. O., Schmid, P. C. & Natarajan, V. The N-acylation-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids 80, 133-142 (1996).
26. Desarnaud, F., Cadas, H. & Piomelli, D. Anandamide amidohydrolase activity in rat brain microsomes: identification and partial characterization, J. Biol. Chem. 270, 6030-6035 (1995).
27. Ueda, N., Kurahashi, Y., Yamamoto, S. & Tokunaga, T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J. Biol. Chem. 270, 23823-23827 (1995).
28. Hillard, C. J., Wilkison, D. M., Edgemont, W. S. & Campbell, W. B. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta 1257, 249-256 (1995).
29. Cravatt, B. F. et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87 (1996).
30. Beltramo, M. et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097 (1997).
31. Civelli, O. in Psychopharmacohgy: The Fourth Generation of Progress (eds. Bloom, F. E. & Kupfer, D. J.) 155-161 (Raven, New York, 1995).
32. Surmeier, D. J., Yan, Z. & Song, W. J. Coordinated expression of dopamine receptors in neostriatal medium spin neurons. Adv. Pharmacol. 42, 1020-1023 (1998).
33. Rinaldi-Carmona, M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244 (1994).
34. Eilam, D. & Szechtman, H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur. J. Pharmacol. 161, 151-157 (1989).
35. Thorn, L., Ashmeade, T. E., Storey, V. J., Routledge, C. & Reavill, C. Evidence to suggest that agonist modulation of hyperlocomotion is via post-synaptic dopamine D2 or D3 receptors. Neuropharmacology 36, 787-792 (1997).
36. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277, 586-594 (1996).
37. 9-THC in the rat. Neuropharmacology 17, 137-144 (1978).
38. Souilhac, J., Poncelet, M., Rinaldi-Carmona, M., Le Fur, G. & Soubrié, P. Intrastriatal injection of cannabinoid receptor agonist induced turning behavior in mice. Pharmacol. Biochem. Behav. 51, 3-7 (1995).
39. 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol. Biochem. Behav. 45, 291-298 (1993).
40. 2+-dependent and independent mechanisms. FEBS Lett. 429, 152-156 (1998).
41. Showalter, V. M., Compton, D. R., Martin, B. R. & Abood, M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278, 989-999 (1996).
42. Matsuda, L. A. Molecular aspects of cannabinoid receptors. Crit. Rev. Neurobiol. 11, 143-166 (1997).
43. Cadas, H., Gaillet, S., Beltramo, M., Venance, L. & Piomelli, D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16, 3934-3942 (1996).
44. Piomelli, D. in Psychopharmacology: The Fourth Generation of Progress (eds. Bloom, F. E. & Kupfer, D. J.) 595-607 (Raven, New York, 1995).
45. Landsman, R. S., Burkey, T. H., Consroe, P., Roeske, W. R. & Yamamura, H. I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol 334, R1-2 (1997).
46. Waddington, J. L., Molloy, A. G., O'Boyle, K. M. & Pugh, M. T. in Neurobiology of Stereotyped Behaviour (eds. Cooper, S. J. & Dourish, C. T.) 64-90 (Clarendon, Oxford, 1990).
47. Fride, E. & Mechoulam, R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231, 313-314 (1993).
48. Pryor, G. T., Larsen, F. F., Husain, S. & Braude, M. C. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacol. Biochem. Behav. 8, 295-318 (1978).
49. Parsons, L. H. & Justice, J. B. J. Quantitative approaches to in vivo brain microdialysis. Crit. Rev. Neurobiol. 8, 189-220 (1994).
50. 3 receptor stimulation enhances cocaine reinforcement. J. Neurochem. 67, 1078-1089 (1996).